Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium and Oxford Biomedica, announced that Boehringer Ingelheim has exercised its options on intellectual property and know-how from the partners to progress and further accelerate the development of a potential, new treatment option for patients with CF.
October 19, 2021
· 6 min read